{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+antivirals", "query": { "intervention": "Oral antivirals" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 235, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+antivirals&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T12:54:19.189Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04392739", "title": "Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Smallpox" ], "interventions": [ { "name": "Tpoxx", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SIGA Technologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "20 Years to 50 Years" }, "enrollment_count": 34, "start_date": "2019-07-19", "completion_date": "2019-12-05", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-22T12:54:19.189Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04392739" }, { "nct_id": "NCT00299897", "title": "SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Human Immunodeficiency Virus" ], "interventions": [ { "name": "SP01A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Samaritan Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 60, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-10-27", "last_synced_at": "2026-09-22T12:54:19.189Z", "location_count": 5, "location_summary": "Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00299897" }, { "nct_id": "NCT05585307", "title": "Study of Novel Antiretrovirals in Participants With HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Bavtavirine", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "Standard of Care (Substudy 01)", "type": "DRUG" }, { "name": "GS-1720", "type": "DRUG" }, { "name": "Standard of Care (Substudy 02)", "type": "DRUG" }, { "name": "GS-6212", "type": "DRUG" }, { "name": "Standard of Care (Substudy 03)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 49, "start_date": "2022-10-26", "completion_date": "2024-03-18", "has_results": true, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-09-22T12:54:19.189Z", "location_count": 38, "location_summary": "Long Beach, California • Los Angeles, California • San Francisco, California + 14 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585307" }, { "nct_id": "NCT01851330", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 647, "start_date": "2013-05", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-22T12:54:19.189Z", "location_count": 52, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01851330" }, { "nct_id": "NCT01525628", "title": "Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "midazolam", "type": "DRUG" }, { "name": "BI 201335", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "tolbutamide", "type": "DRUG" }, { "name": "pegylated interferon", "type": "DRUG" }, { "name": "BI 207127", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 72, "start_date": "2012-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-06-10", "last_synced_at": "2026-09-22T12:54:19.189Z", "location_count": 5, "location_summary": "La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525628" }, { "nct_id": "NCT02639247", "title": "Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2015-12-23", "completion_date": "2017-01-18", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-22T12:54:19.189Z", "location_count": 43, "location_summary": "Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Rialto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639247" }, { "nct_id": "NCT06679140", "title": "A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19 SARS-CoV-2 Infection" ], "interventions": [ { "name": "ibuzatrelvir", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 2330, "start_date": "2024-12-08", "completion_date": "2028-03-02", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-22T12:54:19.189Z", "location_count": 86, "location_summary": "Little Rock, Arkansas • Bakersfield, California • Huntington Park, California + 63 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06679140" }, { "nct_id": "NCT00371150", "title": "Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis B Infection" ], "interventions": [ { "name": "Entecavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 131, "start_date": "2006-11", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-04-16", "last_synced_at": "2026-09-22T12:54:19.189Z", "location_count": 14, "location_summary": "Montgomery, Alabama • Tucson, Arizona • Washington D.C., District of Columbia + 10 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00371150" }, { "nct_id": "NCT03656510", "title": "Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "JNJ-53718678", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "28 Days", "maximum_age": "3 Years", "sex": "ALL", "summary": "28 Days to 3 Years" }, "enrollment_count": 246, "start_date": "2018-11-29", "completion_date": "2022-04-18", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-09-22T12:54:19.189Z", "location_count": 14, "location_summary": "Madera, California • Ventura, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Madera", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Blackfoot", "state": "Idaho" }, { "city": "Nampa", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656510" }, { "nct_id": "NCT02607800", "title": "Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 943, "start_date": "2015-11-16", "completion_date": "2017-01-11", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-22T12:54:19.189Z", "location_count": 47, "location_summary": "Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Rialto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607800" } ] }